Skip to main content
SMS Pharmaceuticals Ltd logo

SMS Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · SMSPHARMA ISIN · INE812G01025 LEI · 335800XXEADQCB7GJ514 BSE.NS Manufacturing
Open in API
Filings indexed 747 across all filing types
Latest filing 2023-02-09 Earnings Release
Country IN India
Listing BSE.NS SMSPHARMA

About SMS Pharmaceuticals Ltd

https://smspharma.com/

SMS Pharmaceuticals Ltd specializes in the development and large-scale manufacturing of Active Pharmaceutical Ingredients (APIs) and advanced intermediates. The organization operates multiple manufacturing units and research centers, maintaining compliance with international regulatory standards including USFDA approvals. Its core product portfolio covers therapeutic areas such as anti-ulcerants, anti-migraine agents, anti-hypertensives, and anti-retrovirals. Beyond its proprietary product line, the company provides Contract Research and Manufacturing Services (CRAMS), offering expertise in process development, chemical synthesis, and analytical validation. The company focuses on delivering high-quality chemical solutions through integrated research and development capabilities, supporting global supply chains with a commitment to technical excellence and operational efficiency.

Recent filings

Filing Released Lang Actions
Press Release
Earnings Release Classification · 95% confidence The document is a press release dated February 9, 2023, announcing the financial results for the third quarter and nine months ended December 31, 2022. It contains summarized financial data such as revenue, EBITDA, and profit after tax, along with segmental performance and management commentary. The document is titled as a 'Press Release' and is addressed to stock exchanges for dissemination. It does not contain comprehensive financial statements or detailed analysis typical of an Interim/Quarterly Report (IR), but rather highlights key financial results and operational updates. This matches the definition of an Earnings Release (ER), which is an initial announcement of quarterly/periodical financial results with key highlights only. The document length (7361 characters) and content support this classification rather than a full interim report or annual report.
2023-02-09 English
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation Classification · 100% confidence The document is addressed to stock exchanges and references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, indicating a regulatory disclosure. It explicitly states it is an "Investor Presentation" for the third quarter and nine months ended 31st December 2022. The content includes company overview, strategic focus, financial highlights, and other detailed information typical of an investor presentation. The document is about 15,000 characters long, which is consistent with a detailed presentation rather than a brief announcement. There is no indication that this is a full financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a transcript, audit report, or other categories. Therefore, the document fits the definition of an Investor Presentation (IP).
2023-02-09 English
Financial Result Updates
Regulatory Filings
2023-02-09 English
Outcome of Board Meeting
Regulatory Filings
2023-02-09 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 90% confidence The document is an invitation and intimation for an Investor's Conference Call scheduled to discuss the company's financial performance for the quarter and nine months ended December 31, 2022. It is addressed to stock exchanges and includes call details and participants. There is no actual financial data or transcript of the call included, only the announcement of the call event. Therefore, this document is best classified as a Call Transcript (CT) invitation or notice. However, since it is only an invitation and not the transcript itself, the closest fitting category is Call Transcript (CT) as it relates directly to the conference call content. Confidence is high given the clear mention of the conference call and financial discussion focus.
2023-02-08 English
Board Meeting — Financial Results
Regulatory Filings Classification · 100% confidence The document text is extremely short (92 characters) and contains only a digital signature with a date, without any substantive content or financial data. There is no indication of a report, announcement, or detailed filing. This matches the criteria for a Regulatory Filing (RNS) as a fallback category for minimal or miscellaneous filings that do not fit other categories.
2023-01-31 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.